Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan

Vaccination against hepatitis B virus in... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/10-55" }, "headline": "Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern...", "datePublished": "2021-01-29T14:17:36", "dateModified": "2024-06-11T17:18:29", "author": [ { "@type": "Person", "name": "Muhammad Nadeem" }, { "@type": "Person", "name": "Syed Asim Ali Shah" }, { "@type": "Person", "name": "Naveed Arshad" }, { "@type": "Person", "name": "Faiza Riaz" }, { "@type": "Person", "name": "Rizwan Saeed Kiani" }, { "@type": "Person", "name": "Muhammad Abdul Quddus" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": " Background Chronic kidney disease (CKD) patients, especially those on hemodialysis, are at increased risk of developing hepatitis B virus (HBV) infection. Guidelines suggest that all patients with CKD should be vaccinated against HBV, but these guidelines are usually not followed. We conducted this study to know the status of vaccination against HBV in CKD patients on regular hemodialysis. Methods This observational descriptive study was conducted at the Department of Medicine, Sheikh Khalifa Bin Zayed Teaching Hospital, Poonch Medical College Rawalakot , and POF Teaching Hospital, Wah Medical College Wah Cantt, from March to July 2019. Patients reporting to the dialysis center of both hospitals on regular dialysis were included in the study. Patient information (HBV vaccination status, age, gender, education, socioeconomic status, duration of CKD and duration of dialysis) were collected on a specially designed questionnaire. The statistical analysis of data was done in SPSS for Windows, version 20. Results A total 149 patients were included in the study, 63.1% were male and 36.9% were female. Out of these 24.2% were uneducated, 33.6% had 1–10 years school education, 38.2% had 10–14 years education, and 4% had more than 14 years education. About 35% patients were from low socioeconomic class, 54% from middle and 11% from higher class. Only 45.6% (n=68) of patients were vaccinated and 54.4% (n=81) were not vaccinated against HBV. Vaccination status was significantly associated with education (p=0.004) and socioeconomic status (p=0.008). Conclusion The HBV status of patients on regular hemodialysis is not satisfactory at the two centers observed. It is associated with education and socioeconomic status of the patient. " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/10-55/v3", "name": "Vaccination against hepatitis B virus in hemodialysis patients: trends..." } } ] } Home Browse Vaccination against hepatitis B virus in hemodialysis patients: trends... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Nadeem M, Shah SAA, Arshad N et al. Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.12688/f1000research.28045.3 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Research Article Revised Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] Muhammad Nadeem https://orcid.org/0000-0002-6262-7365 1 , Syed Asim Ali Shah https://orcid.org/0000-0001-5722-3879 2 , Naveed Arshad 3 , Faiza Riaz 2 , Rizwan Saeed Kiani 4 , Muhammad Abdul Quddus 4 Muhammad Nadeem https://orcid.org/0000-0002-6262-7365 1 , Syed Asim Ali Shah https://orcid.org/0000-0001-5722-3879 2 , [...] Naveed Arshad 3 , Faiza Riaz 2 , Rizwan Saeed Kiani 4 , Muhammad Abdul Quddus 4 PUBLISHED 11 Jun 2024 Author details Author details 1 Department of Medicine, Poonch Medical College, Rawalakot, Azad Kashmir, Pakistan 2 Department of Medicine, Wah Medical College, Wah Cantt, Punjab, Pakistan 3 Department of Rehabilitation Medicine, Islamabad Medical and Dental College, Islamabad, Pakistan 4 Department of Gastroenterology, Poonch Medical College, Rawalakot, Azad Kashmir, Pakistan Muhammad Nadeem Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Writing – Original Draft Preparation, Writing – Review & Editing Syed Asim Ali Shah Roles: Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Writing – Review & Editing Naveed Arshad Roles: Data Curation, Formal Analysis, Software, Validation, Visualization, Writing – Review & Editing Faiza Riaz Roles: Investigation, Methodology, Resources, Writing – Original Draft Preparation Rizwan Saeed Kiani Roles: Data Curation, Investigation, Methodology, Resources, Writing – Review & Editing Muhammad Abdul Quddus Roles: Investigation, Methodology, Project Administration, Validation, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Background Chronic kidney disease (CKD) patients, especially those on hemodialysis, are at increased risk of developing hepatitis B virus (HBV) infection. Guidelines suggest that all patients with CKD should be vaccinated against HBV, but these guidelines are usually not followed. We conducted this study to know the status of vaccination against HBV in CKD patients on regular hemodialysis. Methods This observational descriptive study was conducted at the Department of Medicine, Sheikh Khalifa Bin Zayed Teaching Hospital, Poonch Medical College Rawalakot , and POF Teaching Hospital, Wah Medical College Wah Cantt, from March to July 2019. Patients reporting to the dialysis center of both hospitals on regular dialysis were included in the study. Patient information (HBV vaccination status, age, gender, education, socioeconomic status, duration of CKD and duration of dialysis) were collected on a specially designed questionnaire. The statistical analysis of data was done in SPSS for Windows, version 20. Results A total 149 patients were included in the study, 63.1% were male and 36.9% were female. Out of these 24.2% were uneducated, 33.6% had 1–10 years school education, 38.2% had 10–14 years education, and 4% had more than 14 years education. About 35% patients were from low socioeconomic class, 54% from middle and 11% from higher class. Only 45.6% (n=68) of patients were vaccinated and 54.4% (n=81) were not vaccinated against HBV. Vaccination status was significantly associated with education (p=0.004) and socioeconomic status (p=0.008). Conclusion The HBV status of patients on regular hemodialysis is not satisfactory at the two centers observed. It is associated with education and socioeconomic status of the patient. READ ALL READ LESS Keywords Dialysis, Education, Hepatitis B, Socioeconomic class, Vaccination Corresponding Author(s) Muhammad Nadeem ( [email protected] ) Close Corresponding author: Muhammad Nadeem Competing interests: No competing interests were disclosed. Grant information: The author(s) declared that no grants were involved in supporting this work. Copyright: © 2024 Nadeem M et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Nadeem M, Shah SAA, Arshad N et al. Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.12688/f1000research.28045.3 ) First published: 29 Jan 2021, 10 :55 ( https://doi.org/10.12688/f1000research.28045.1 ) Latest published: 11 Jun 2024, 10 :55 ( https://doi.org/10.12688/f1000research.28045.3 ) Revised Amendments from Version 2 We have made small changes by adding some sentences in discussion regarding patients education about vaccination as advised by reviewer. We have made small changes by adding some sentences in discussion regarding patients education about vaccination as advised by reviewer. See the authors' detailed response to the review by Antonio Bertoletti See the authors' detailed response to the review by Lionel Rostaing See the authors' detailed response to the review by Chenhua Liu READ REVIEWER RESPONSES Introduction Chronic kidney disease (CKD) is a global health problem; estimated global prevalence is 11–13% with majority of the patients having stage 3 disease 1 . It is an immunosuppressive state, so CKD patients are at increased risk of developing many infections; some of these infections are vaccine preventable 2 . Hepatitis B virus (HBV) infection is among one of those infections. Like other high risk groups including IV drug abusers, homosexual men, having history of piercing and blood transfusions, it is more prevalent in CKD patients as compared to the general population 3 – 5 . High risk of HBV among hemodialysis patients is due to increased exposure to blood products, frequent cannulation and shared hemodialysis equipment 6 . HBV infection in CKD patients varies globally and correlates with the prevalence in the general population. Decreasing trends have been seen in developed countries; in the US it decreased from 7.8% in 1976 to 1% in 2002 3 . The exact prevalence among CKD and dialysis patients in the developing world, including Pakistan, is not well known. There are scattered reports, mostly single-centre surveys; according to these surveys hepatitis B surface antigen (HBsAg) carrier rate ranges between 2% to 20% 6 . In Pakistan, the prevalence rate is about 4% in the general population 7 , indicating that it will be more than 4% in CKD patients. Prevention is the best option in the general population, as well as in high risk groups to reduce the prevalence of hepatitis B infection because treatment is lengthy, costly and not 100% effective. As HBV can be transmitted easily from the medical equipment used during dialysis, as it remains viable and stable in the environment for weeks at room temperature 8 , vaccination against HBV is most effective way to prevent it in CKD patients on hemodialysis. Complete vaccination was found to be protective in ≥90% in the general population, even 30 years after vaccination 9 . Although response is not good in chronic renal failure patients, up to 40% were found to be non-responders in some studies 3 , 10 . Still routine vaccinations of patients and healthcare workers has dramatically reduced the prevalence of HBV infection in hemodialysis patients 11 . It was found 70% lower among vaccinated patients as compared to non-vaccinated hemodialysis patients 12 . Guidelines from nephrology societies and Centers for Disease Control and Prevention suggest that all patients with CKD should be vaccinated against HBV 2 . Special formulation of recombinant vaccine is advised, either higher dosage or increased number of doses (4 doses) should be administered for good results 2 . Although guidelines strongly recommend vaccination of CKD patients against vaccine preventable diseases, it has been shown that they are not in fact routinely vaccinated against HBV. A study published in the UK showed that only 46% dialysis units were routinely immunizing patients according to the Renal Association’s recommendations 13 , while only 20% of patients were found to be vaccinated in a study conducted in Pakistan 14 . Vaccination against HBV decreases the overall mortality in CKD patients, but, to the best of our knowledge, no recent data is available regarding the status of vaccination against HBV in CKD patients internationally. In developing countries, including Pakistan where hepatitis B is still a common problem, there is limited data available on this topic. The aim of this study was to observe the immunization status of CKD patients on regular hemodialysis against hepatitis B in Pakistan. The data can help in future for necessary measures to improve the vaccination against hepatitis B in CKD patients in order to reduce the HBV related morbidity and mortality in hemodialysis patients. Methods Study design and sampling This was an observational descriptive study conducted at the Department of Medicine, Sheikh Khalifa Bin Zayed Hospital, Rawalakot and POF Hospital, Wah Cantt, from March 2019 to July 2019. Calculated sample size was 139 by using the formula for cross sectional studies 15 . Patients reporting to the dialysis centre of both hospitals with a diagnosis of CKD on regular dialysis of any age were included in the study by consecutive sampling. CKD was defined as individuals with markers of kidney damage or those with eGFR<60 mL/min per 1.73 m 2 regardless of the cause 16 . Hepatitis B surface antigen positive, newly diagnosed CKD patients not on dialysis and patients not sure about their vaccination status were excluded from the study. Data collection Data was collected using a structured questionnaire ( Extended data 17 ). The questionnaire included items intended to assess socio-demographic variables and hepatitis B vaccination status of the patients. The questionnaire was filled by the authors of the study after interviewing the participants. Every participant was interviewed before their dialysis session when they reported to the dialysis center for the scheduled dialysis. Record of dialysis centers was checked regarding vaccination status of patients to validate the patients statement, if any contradiction was found, such patient was excluded from the study. Socio-demographic factors Age was entered in years, gender was entered as male or female, education level was considered as uneducated (those not able to read and write), up to secondary level education (1 to 10 years education), secondary level to graduation (10–14 years education) and post-graduation (more than 14 years education). Socioeconomic status was defined as lower class (monthly income ≤ 20000 Pakistani Rupees), middle class (monthly income 21000 to 99000 Pakistani Rupees) and upper class (monthly income ≥ 100000 Pakistani Rupees) based on gross monthly income and access to educational and healthcare facilities. Duration of CKD was considered in months. Vaccination status Patients were interviewed in detail about their vaccination status against hepatitis B. Only those were considered as vaccinated who completed the course of vaccination of 4 doses or 3 doses at an interval specified for hepatitis B vaccination. Those who did not receive vaccine at all and those who had an incomplete course were considered as unvaccinated. Statistical analysis The statistical analysis of data was done in SPSS for Windows, version 20. Means and standard deviations were calculated for quantitative variables like age and duration of CKD. Frequencies were calculated for gender, education, socioeconomic status and vaccination status of hepatitis B. Chi square test was applied to see the relation between different factors and status of vaccination. P ≤0.05 was considered as significant. Ethics statement Ethical approval was obtained from Hospital Research Ethics Committee of POF Teaching Hospital, Wah Cantt (letter no. POFH/ERC/99053/05) and Hospital Research Ethics Committee of Sheikh Khalifa Bin Zayed Teaching Hospital (letter no. SKBZ/REC/019/08). Informed verbal consent to participate was obtained from the patients or their close relatives (when patients were unable to comprehend the researchers due to old age or uremic encephalopathy) where relevant. Verbal consent over written consent was taken because many patients were uneducated and unable to read a consent forms or were reluctant to sign a document. The ethics committee gave permission for this route of consent to be obtained. Consent for minors was taken from one of their parents. Results A total of 200 patients were asked to take part in the study, but only 149 responded. A total of 63.1% (n=94) were male and 36.9% (n=55) were female. Mean age was 50.5±16.7 years, with minimum age of 7 years and maximum 83 years. Mean duration of CKD was 38.9±47.2 months. Out of these 149 patients, 24.2% (n=36) were uneducated, 33.6% (n=50) had 1–10 years school education (up to secondary level), whereas 38.2% (n=57) had 10–14 years education (secondary level to graduation) and 4% (n=6) had more than 14 years education (post-graduation). About 35.6% (n=53) patients were from low socioeconomic class, 53.6% (n=80) from middle, and 10.8% (n=16) from higher class. Only 45.6% (n=68) patients were vaccinated and 54.4% (n=81) were not vaccinated against HBV ( Table 1 ). Table 1. Descriptive statistics of vaccination status in patients (n=149). N % Vaccination status Yes 68 45.6 No 81 54.4 Total 149 100.0 A significant association was found between vaccination status and education of the patient; better educated patients were more likely to be vaccinated ( Table 2 ). A significant association was also found between vaccination and socioeconomic status of the patients; patients from middle and upper classes were more likely to be vaccinated as compared to lower class. ( Table 3 ). Vaccination status of the patients was not significantly associated with age (p= 0.540), gender (p= 0.517), and duration of CKD (p= 0.719). Table 2. Association between education of patients and vaccination status. Hepatitis B vaccination status, n (%) Total (n= 149) p-value Yes (n = 68) No n = 81 Uneducated 14 (39) 22 (61) 36 0.004 Up to secondary level 20 (40) 30 (60) 50 Secondary level to graduation 34 (59.6) 23 (40.4) 57 Post- graduation 5 (83.3) 1 (16.7) 6 Table 3. Association between socioeconomic class of patients and vaccination status. Hepatitis B vaccination status, n (%) Total (n= 149) p-value Yes (n = 68) No (n = 81) Lower 15 (30) 37 (70) 53 0.008 Middle 42 (52.5) 38 (47.5) 80 Upper 11 (68.7) 5 (31.3) 16 Discussion In our study, we found that 45.6% patients of CKD on regular dialysis were found to be vaccinated against HBV. We concluded that education and socioeconomic status are two important factors associated with status of vaccination, and vaccination status was not associated with age, gender, and duration of CKD. Results showed that 63% patients were male, and the mean age of patients was 50 years. This suggests that more male patients are on hemodialysis and CKD is also more common in the older age group. This is the same as the United States Renal Data System 2011 Annual Data Report that showed that the initiation of dialysis was much higher in males as compared to females 18 . However, a meta-analysis reported that in some studies CKD was more common in females, while in other studies it was more common in males 1 . Many studies showed that CKD is more common in an older age group 1 , comparable with our findings. For example, in a study conducted in India 19 , the mean age was 51 years in CKD patients, while in a Chinese study it was found to 63.6 years 20 , almost the same as in our study. We did not find any association between status of vaccination and age or gender; this was also concluded by Amjad et al. in a study conducted in Pakistan 14 . Nephrology societies and Centre for Disease Control and Prevention recommends that all CKD patients should be vaccinated against HBV 2 . These guidelines are not followed even in the developed world; 73.1% patients of CKD were found vaccinated in US 21 , and only 31% patients were vaccinated in a study conducted in Belgium 22 . Our results are also not encouraging, only 45.6% were found vaccinated, while in another study from Pakistan only 20% patients were vaccinated, consistent with our results 14 . A study conducted in Brazil showed better vaccination rates compared to our results, almost 60% patients were completely vaccinated, and another 15% were partially vaccinated 22 . The low vaccination rate in Pakistan indicates that dialysis centers and nephrologists are not following the guidelines of nephrology societies regarding vaccination against hepatitis B. Our study reported that vaccination status in dialysis patients was significantly associated with socioeconomic class and education of the patients. A vaccinated status was found to be higher in CKD patients with better socioeconomic status in another study conducted in Pakistan 14 . Another study conducted by Ertekin et al. showed that better socioeconomic status was associated with higher rates of vaccination in the general population 23 . These results are same as we found in our study. Low vaccination rates among lower socioeconomic groups may be due to non-affordability. As far as education is concerned, no association was found between vaccination against HBV of CKD patients and education in a study conducted by Amjad et al. 14 , which differs from our results. Studies from the general population and healthcare workers showed that education was significantly associated with vaccination status against HBV, comparable to our results 24 – 26 . Individuals who have more education may be better aware of the preventive role of vaccination, which may be the cause of better vaccination status in higher educated people. It shows that awareness about vaccination and its preventive role is important. In order to improve the status of vaccination we suggest that CKD patients should be educated about the importance of vaccination in preventing the HBV infection by implementing the special educational programs for these patients. Vaccination rates can also be increased by free vaccination programs for CKD and hemodialysis patients. Our study is subject to some limitations. First, we only included those patients who were on regular dialysis. Second, only two dialysis centers were included in the study and few factors were studied related to vaccination status. We recommend future studies to include all patients of CKD from many centers. Conclusion Currently dialysis centers are not following guidelines regarding vaccination against HBV in hemodialysis patients. Vaccination status of patients on hemodialysis is not satisfactory in dialysis centers we sampled in Northern Pakistan. We found that vaccination status is significantly associated with education and socioeconomic status of the patients. Data availability Underlying data Figshare: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan, doi.org/10.6084/m9.figshare.13359713.v1 17 . Extended data Figshare: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan, https://doi.org/10.6084/m9.figshare.13359713.v1 17 . This project contains the following extended data: - Copy of the questionnaire used in the study. Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication). Faculty Opinions recommended References 1. Hill NR, Fatoba ST, Oke JL, et al. : Global prevalence of Chronic Kidney Disease - a systematic review and meta-analysis. PLoS One. 2016; 11 (7): e0158765. PubMed Abstract | Publisher Full Text | Free Full Text 2. Guidelines for vaccination in patients with Chronic Kidney Disease. Indian J Nephrol. 2016; 26 (Suppl 1): S15–S18. Free Full Text 3. Grzegorzewska AE: Hepatitis B vaccination in Chronic Kidney Disease: review of evidence in non-dialyzed patients. Hepat Mon. 2012; 12 (11): e7359. PubMed Abstract | Publisher Full Text | Free Full Text 4. Falla AM, Hofstraat SHI, Duffell E, et al. : Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis. 2018; 18 (1): 79. PubMed Abstract | Publisher Full Text | Free Full Text 5. Ziaee M, Ebrahimzadeh A, Azarkar Z, et al. : Seroprevalence and risk factors for hepatitis B in an adult population: the first report from Birjand, South Khorasan, Iran. Hepat Mon. 2016; 16 (9): e36452. PubMed Abstract | Publisher Full Text | Free Full Text 6. Somi MH, Hajipour B: Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvants. ISRN Gastroenterol. 2012; 2012 : 960413. PubMed Abstract | Free Full Text 7. Mehmood S, Raza H, Abid F, et al. : National prevalence rate of hepatitis B and C in Pakistan and its risk factors. J Public Health. 2019; 28 : 751–764. Publisher Full Text 8. Than TT, Jo E, Todt D, et al. : High environmental stability of Hepatitis B Virus and inactivation requirements for chemical biocides. J Infect Dis. 2019; 219 (7): 1044–48. PubMed Abstract | Publisher Full Text | Free Full Text 9. Bruce MG, Bruden D, Hurlburt D, et al. : Antibody levels and protection after Hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 2016; 214 (1): 16–22. PubMed Abstract | Publisher Full Text 10. Malaki M: Factors affecting on hepatitis B seroprotection in hemodialysis patients. Saudi J Kidney Dis Transpl. 2017; 28 (3): 672–74. PubMed Abstract | Publisher Full Text 11. Wasley A, Kruszon-Moran D, Kuhnert W, et al. : The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010; 202 (2): 192–201. PubMed Abstract | Publisher Full Text 12. Grzegorzewska AE: Prophylactic vaccinations in Chronic Kidney Disease: current status. Hum Vaccin Immunother. 2015; 11 (11): 2599–2605. PubMed Abstract | Publisher Full Text | Free Full Text 13. Ray S, Samuel T, Hawker J, et al. : Hepatitis B immunisation in renal units in the United Kingdom: questionnaire study. BMJ. 2002; 324 (7342): 877–78. PubMed Abstract | Publisher Full Text | Free Full Text 14. Amjad A, Kumar J, Chaudary N, et al. : Hepatitis B vaccination status in Chronic Kidney Disease: experience at Pakistan Institute of Medical Sciences. Cureus. 2019; 11 (7): e5282. PubMed Abstract | Publisher Full Text | Free Full Text 15. Charan J, Biswas T: How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013; 35 (2): 121–6. PubMed Abstract | Publisher Full Text | Free Full Text 16. Webster AC, Nagler EV, Morton RL, et al. : Chronic Kidney Disease. Lancet. 2017; 389 (10075): 1238–1252. PubMed Abstract | Publisher Full Text 17. Nadeem M, Sha SAA, Arshad N, et al. : Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan. figshare. Dataset. 2020. http://www.doi.org/10.6084/m9.figshare.13359713.v1 18. United States Renal Data System: 2011 Annual Data Report. Accessed 21 September 2019. Reference Source 19. Rajapurkar MM, John GT, Kirpalani AL, et al. : What do we know about Chronic Kidney Disease in India: first report of the Indian CKD registry. BMC Nephrol. 2012; 13 : 10. PubMed Abstract | Publisher Full Text | Free Full Text 20. Zhang L, Wang F, Wang L: Prevalence of Chronic Kidney Disease in China: a cross-sectional survey. Lancet. 2012; 379 (9818): 815–22. PubMed Abstract | Publisher Full Text 21. Ayoola R, Larion S, Poppers DM, et al. : Clinical factors associated with hepatitis B screening and vaccination in high-risk adults. World J Hepatol. 2019; 11 (1): 86–98. PubMed Abstract | Publisher Full Text | Free Full Text 22. Boey L, Bosmans E, Ferreira LB, et al. : Vaccination coverage of recommended vaccines and determinants of vaccination in at-risk groups. Hum Vaccin Immunother. 2020; 16 (9): 2136–43. PubMed Abstract | Publisher Full Text | Free Full Text 23. Guimarães MNC, Facincani T, de Sousa dos Santos S: Hepatitis B status in hemodialysis patients. Arq Gastroenterol. 2017; 54 (4): 356–58. PubMed Abstract | Publisher Full Text 24. Ertekin V, Selimoğlu MA: Effects of Several Socio-demographic factors on hepatitis B immunization rates. Eur J Gasteroenterol Hepatol. 2004; 16 (7): 719. PubMed Abstract | Publisher Full Text 25. Omotowo IB, Meka IA, Ijoma UN, et al. : Uptake of hepatitis B vaccination and its determinants among health care workers in a tertiary health facility in Enugu, South-East, Nigeria. BMC Infect Dis. 2018; 18 (1): 288. PubMed Abstract | Publisher Full Text | Free Full Text 26. Khan J, Shil A, Mohanty SK: Hepatitis B vaccination coverage across India: exploring the spatial heterogeneity and contextual determinants. BMC Public Health. 2019; 19 (1): 1263. PubMed Abstract | Publisher Full Text | Free Full Text Comments on this article Comments (0) Version 3 VERSION 3 PUBLISHED 29 Jan 2021 ADD YOUR COMMENT Comment Author details Author details 1 Department of Medicine, Poonch Medical College, Rawalakot, Azad Kashmir, Pakistan 2 Department of Medicine, Wah Medical College, Wah Cantt, Punjab, Pakistan 3 Department of Rehabilitation Medicine, Islamabad Medical and Dental College, Islamabad, Pakistan 4 Department of Gastroenterology, Poonch Medical College, Rawalakot, Azad Kashmir, Pakistan Muhammad Nadeem Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Writing – Original Draft Preparation, Writing – Review & Editing Syed Asim Ali Shah Roles: Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Writing – Review & Editing Naveed Arshad Roles: Data Curation, Formal Analysis, Software, Validation, Visualization, Writing – Review & Editing Faiza Riaz Roles: Investigation, Methodology, Resources, Writing – Original Draft Preparation Rizwan Saeed Kiani Roles: Data Curation, Investigation, Methodology, Resources, Writing – Review & Editing Muhammad Abdul Quddus Roles: Investigation, Methodology, Project Administration, Validation, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information The author(s) declared that no grants were involved in supporting this work. Article Versions (3) version 3 Revised Published: 11 Jun 2024, 10:55 https://doi.org/10.12688/f1000research.28045.3 version 2 Revised Published: 29 Apr 2021, 10:55 https://doi.org/10.12688/f1000research.28045.2 version 1 Published: 29 Jan 2021, 10:55 https://doi.org/10.12688/f1000research.28045.1 Copyright © 2024 Nadeem M et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Nadeem M, Shah SAA, Arshad N et al. Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.12688/f1000research.28045.3 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 3 VERSION 3 PUBLISHED 11 Jun 2024 Revised Views 0 Cite How to cite this report: Bertoletti A. Reviewer Report For: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.5256/f1000research.167732.r351017 ) The direct URL for this report is: https://f1000research.com/articles/10-55/v3#referee-response-351017 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 31 Dec 2024 Antonio Bertoletti , Duke-NUS Medical School, Singapore, Singapore Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.167732.r351017 This is an observational study based on a questionnaire. The authors derived from this questionnaire that about half of the patients on regular hemodialysis were vaccinated against HBV and that the vaccination status was linked with socioeconomic ... Continue reading READ ALL This is an observational study based on a questionnaire. The authors derived from this questionnaire that about half of the patients on regular hemodialysis were vaccinated against HBV and that the vaccination status was linked with socioeconomic status. There is nothing more. No analysis of HBV prevalence..no test whether the vaccinated here reallly Ab-HBs positive. I don't have any comment except to say that the results are not exactly of high interest. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: HBv pathogenesis. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Bertoletti A. Reviewer Report For: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.5256/f1000research.167732.r351017 ) The direct URL for this report is: https://f1000research.com/articles/10-55/v3#referee-response-351017 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 30 Jan 2025 Muhammad Nadeem , Department of Medicine, Poonch Medical College, Rawalakot, Pakistan 30 Jan 2025 Author Response I would like to thank you for your precocious time and valuable comments about our article; this will guide us in future as well. You rightly pointed out that ... Continue reading I would like to thank you for your precocious time and valuable comments about our article; this will guide us in future as well. You rightly pointed out that we did not mention about the prevalence of Hep B. We did the Hep B surface antigen but all those patients who were Hep B surface antigen positive were excluded from the study as mentioned in Study design and sampling " Hepatitis B surface antigen positive, newly diagnosed CKD patients not on dialysis and patients not sure about their vaccination status were excluded from the study" that's why it was not mentioned. You also rightly mentioned that results are not interesting but in our circumstances where dialysis centers and nephrologist are not following the guidelines of vaccinating every CKD patients these results can be used to sensitize them to improve the vaccination rates. I hope you will again review the article considering our limitations and local circumstances as for as the results are concerned and approve our article without reservations. I would like to thank you for your precocious time and valuable comments about our article; this will guide us in future as well. You rightly pointed out that we did not mention about the prevalence of Hep B. We did the Hep B surface antigen but all those patients who were Hep B surface antigen positive were excluded from the study as mentioned in Study design and sampling " Hepatitis B surface antigen positive, newly diagnosed CKD patients not on dialysis and patients not sure about their vaccination status were excluded from the study" that's why it was not mentioned. You also rightly mentioned that results are not interesting but in our circumstances where dialysis centers and nephrologist are not following the guidelines of vaccinating every CKD patients these results can be used to sensitize them to improve the vaccination rates. I hope you will again review the article considering our limitations and local circumstances as for as the results are concerned and approve our article without reservations. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 30 Jan 2025 Muhammad Nadeem , Department of Medicine, Poonch Medical College, Rawalakot, Pakistan 30 Jan 2025 Author Response I would like to thank you for your precocious time and valuable comments about our article; this will guide us in future as well. You rightly pointed out that ... Continue reading I would like to thank you for your precocious time and valuable comments about our article; this will guide us in future as well. You rightly pointed out that we did not mention about the prevalence of Hep B. We did the Hep B surface antigen but all those patients who were Hep B surface antigen positive were excluded from the study as mentioned in Study design and sampling " Hepatitis B surface antigen positive, newly diagnosed CKD patients not on dialysis and patients not sure about their vaccination status were excluded from the study" that's why it was not mentioned. You also rightly mentioned that results are not interesting but in our circumstances where dialysis centers and nephrologist are not following the guidelines of vaccinating every CKD patients these results can be used to sensitize them to improve the vaccination rates. I hope you will again review the article considering our limitations and local circumstances as for as the results are concerned and approve our article without reservations. I would like to thank you for your precocious time and valuable comments about our article; this will guide us in future as well. You rightly pointed out that we did not mention about the prevalence of Hep B. We did the Hep B surface antigen but all those patients who were Hep B surface antigen positive were excluded from the study as mentioned in Study design and sampling " Hepatitis B surface antigen positive, newly diagnosed CKD patients not on dialysis and patients not sure about their vaccination status were excluded from the study" that's why it was not mentioned. You also rightly mentioned that results are not interesting but in our circumstances where dialysis centers and nephrologist are not following the guidelines of vaccinating every CKD patients these results can be used to sensitize them to improve the vaccination rates. I hope you will again review the article considering our limitations and local circumstances as for as the results are concerned and approve our article without reservations. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Version 2 VERSION 2 PUBLISHED 29 Apr 2021 Revised Views 0 Cite How to cite this report: Rostaing L. Reviewer Report For: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.5256/f1000research.56293.r153704 ) The direct URL for this report is: https://f1000research.com/articles/10-55/v2#referee-response-153704 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 08 Nov 2022 Lionel Rostaing , Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, Centre Hospitalier Universitaire Grenoble Alpes (CHU), Université Grenoble Alpes, Grenoble, France Approved VIEWS 0 https://doi.org/10.5256/f1000research.56293.r153704 This is an observational descriptive study that was conducted in 2 departments of hemodialysis in Azad-Kashmir (Pakistan). The study took place between March and July 2019. HBV infection still remains a public health problem in many Asian countries. In addition, ... Continue reading READ ALL This is an observational descriptive study that was conducted in 2 departments of hemodialysis in Azad-Kashmir (Pakistan). The study took place between March and July 2019. HBV infection still remains a public health problem in many Asian countries. In addition, its prevalence amongst hemodialysis patients is increased (i.e., because of nosocomial transmission). It is therefore of utmost importance to limit the spread of HVB infection in hemodialysis patients: this can only be achieved with universal HBV vaccination. However, many people are reluctant to HBV vaccination. In this original work, Nadeem M. et al . looked at the factors associated with HBV vaccination in a cohort of 149 hemodialysis patients; of these 63.1% were male. Overall, 24.2% were uneducated, 33.6% had 1-10 years school education, 38.2% had 10-14 years education, and 4% had more than 14 years education. In addition, about 35% patients were from low socioeconomic class, 54% from middle and 11% from higher class. At the end the of the day, only 45.6% (n=68) of patients were vaccinated. In addition, vaccination status was significantly associated with education (p=0.004) and socioeconomic status (p=0.008). In the discussion’s section the authors should emphasize the fact that educational programs should be implemented in chronic kidney disease patients as well as in hemodialysis ones in order that they are aware of the importance of « fighting » HBV infection. Indeed, HBV vaccination should be done for free as well as the boosters (is it the case in Pakistan?). Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Nephrology, Dialysis, Kidney transplantation, Transplant Immunology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Rostaing L. Reviewer Report For: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.5256/f1000research.56293.r153704 ) The direct URL for this report is: https://f1000research.com/articles/10-55/v2#referee-response-153704 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 16 Nov 2022 Muhammad Nadeem , Department of Medicine, Poonch Medical College, Rawalakot, Pakistan 16 Nov 2022 Author Response We would like to thank the reviewer for his valuable time and comments on our article; this will be very helpful for us in future research as well. Competing Interests: No competing interests were disclosed. We would like to thank the reviewer for his valuable time and comments on our article; this will be very helpful for us in future research as well. We would like to thank the reviewer for his valuable time and comments on our article; this will be very helpful for us in future research as well. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 16 Nov 2022 Muhammad Nadeem , Department of Medicine, Poonch Medical College, Rawalakot, Pakistan 16 Nov 2022 Author Response We would like to thank the reviewer for his valuable time and comments on our article; this will be very helpful for us in future research as well. Competing Interests: No competing interests were disclosed. We would like to thank the reviewer for his valuable time and comments on our article; this will be very helpful for us in future research as well. We would like to thank the reviewer for his valuable time and comments on our article; this will be very helpful for us in future research as well. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Liu C. Reviewer Report For: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.5256/f1000research.56293.r84207 ) The direct URL for this report is: https://f1000research.com/articles/10-55/v2#referee-response-84207 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 29 Apr 2021 Chenhua Liu , Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan Not Approved VIEWS 0 https://doi.org/10.5256/f1000research.56293.r84207 The authors claimed that all CKD patients should be vaccinated for HBV by guidelines. However, the authors should be more cautious about the claims, all the guidelines did not recommend vaccination for all CKD patients for HBV. ... Continue reading READ ALL The authors claimed that all CKD patients should be vaccinated for HBV by guidelines. However, the authors should be more cautious about the claims, all the guidelines did not recommend vaccination for all CKD patients for HBV. eg. the MMWR report (cited by the author in the revision) clearly indicated that "Vaccination of individuals who possess antibodies against HBV from a previous infection is not necessary" and "Pre-vaccination serologic screening for susceptibility". Furthermore, the CDC guideline did not mention universal HBV vaccination. The author focused on hemodialysis patients. Although eGFR < 60 was defined as CKD, I wondered if patients with eGFR ranging from 15-60 need hemodialysis. The illustration of CKD as a cutoff value of 60 is meaningless. Competing Interests: No competing interests were disclosed. Reviewer Expertise: Hepatitis B, hepatitis C, chronic kidney disease I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Liu C. Reviewer Report For: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.5256/f1000research.56293.r84207 ) The direct URL for this report is: https://f1000research.com/articles/10-55/v2#referee-response-84207 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 10 Jun 2021 Muhammad Nadeem , Department of Medicine, Poonch Medical College, Rawalakot, Pakistan 10 Jun 2021 Author Response 1. The authors claimed that all CKD patients should be vaccinated for HBV by guidelines. However, the authors should be more cautious about the claims, all the guidelines did not ... Continue reading 1. The authors claimed that all CKD patients should be vaccinated for HBV by guidelines. However, the authors should be more cautious about the claims, all the guidelines did not recommend vaccination for all CKD patients for HBV. eg. the MMWR report (cited by the author in the revision) clearly indicated that "Vaccination of individuals who possess antibodies against HBV from a previous infection is not necessary" and "Pre-vaccination serologic screening for susceptibility". Furthermore, the CDC guideline did not mention universal HBV vaccination. Response : Reviewer pointed out that "Vaccination of individuals who possess antibodies against HBV from a previous infection is not necessary” and rejected the article on the basis of this statement. No doubt that these individuals do not need the vaccination but routine pre vaccine serology to rule out immune individual in not recommended in any guideline. MMWR report which summarizes recommendations from the Advisory Committee on Immunization Practices (ACIP) and CDC clearly mentions “ACIP recommends vaccination of adults at risk for HBV infection, including universal vaccination of adults in settings in which a high proportion have risk factors for HBV infection” 1 supporting our claims of vaccination of all individuals on hemodialysis. ACIP also mentions “Serologic testing should not be a barrier to vaccination of susceptible persons 1 ” and “Vaccination of persons immune to HBV because of current or previous infection or HepB vaccination does not increase the risk for adverse events” 1 . It clearly indicates that pre vaccination serology is not necessary. CDC also adopted these guidelines. ( https://www.cdc.gov/hepatitis/hbv/vaccadults.htm ) Further reviewer stated "Pre-vaccination serologic screening for susceptibility" but the Advisory Committee on Immunization Practices states “Testing is not a requirement for vaccination, and in settings where testing is not feasible, vaccination of recommended persons should continue 1 ”. Routine pre vaccination serology is also not recommended by WHO especially when it is not cost effective 2 . As routine pre vaccination serology except HBsAg is not done in our setup, so we included all patients except HBsAg positive patient. This is in accordance with Advisory Committee on Immunization Practices, CDC and WHO guidelines in view of above mentioned statements contrary to the perception of reviewer. 1. Sarah Schillie, MD; Claudia Vellozzi, MD; Arthur Reingold, MD; Aaron Harris, MD; Penina Haber, MPH; John W. Ward, MD; Noele P. Nelson, MD, Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and Reports / January 12, 2018 / 67(1);1–31. 2. World Health Organization. (Hepatitis B vaccines: WHO position paper, July 2017 – Recommendations [published online July 22, 2017]. Vaccine. doi: 10.1016/j.vaccine.2017.07. 2. The author focused on hemodialysis patients. Although eGFR < 60 was defined as CKD, I wondered if patients with eGFR ranging from 15-60 need hemodialysis. The illustration of CKD as a cutoff value of 60 is meaningless. Response : Reviewer either did not read the methodology section in detail or he was unable to comprehend the need of this definition. We want to explain this; usually there are two types of patient on hemodialysis. 1. Patients of CKD 2. Patients with AKI, as our study was limited to CKD patients there was need to define CKD. We included the internationally accepted definition of CKD with reference, we also requested the reviewer in our previous response to provide any alternate definition of CKD with reference, if this definition is not appropriate for this article. 1. The authors claimed that all CKD patients should be vaccinated for HBV by guidelines. However, the authors should be more cautious about the claims, all the guidelines did not recommend vaccination for all CKD patients for HBV. eg. the MMWR report (cited by the author in the revision) clearly indicated that "Vaccination of individuals who possess antibodies against HBV from a previous infection is not necessary" and "Pre-vaccination serologic screening for susceptibility". Furthermore, the CDC guideline did not mention universal HBV vaccination. Response : Reviewer pointed out that "Vaccination of individuals who possess antibodies against HBV from a previous infection is not necessary” and rejected the article on the basis of this statement. No doubt that these individuals do not need the vaccination but routine pre vaccine serology to rule out immune individual in not recommended in any guideline. MMWR report which summarizes recommendations from the Advisory Committee on Immunization Practices (ACIP) and CDC clearly mentions “ACIP recommends vaccination of adults at risk for HBV infection, including universal vaccination of adults in settings in which a high proportion have risk factors for HBV infection” 1 supporting our claims of vaccination of all individuals on hemodialysis. ACIP also mentions “Serologic testing should not be a barrier to vaccination of susceptible persons 1 ” and “Vaccination of persons immune to HBV because of current or previous infection or HepB vaccination does not increase the risk for adverse events” 1 . It clearly indicates that pre vaccination serology is not necessary. CDC also adopted these guidelines. ( https://www.cdc.gov/hepatitis/hbv/vaccadults.htm ) Further reviewer stated "Pre-vaccination serologic screening for susceptibility" but the Advisory Committee on Immunization Practices states “Testing is not a requirement for vaccination, and in settings where testing is not feasible, vaccination of recommended persons should continue 1 ”. Routine pre vaccination serology is also not recommended by WHO especially when it is not cost effective 2 . As routine pre vaccination serology except HBsAg is not done in our setup, so we included all patients except HBsAg positive patient. This is in accordance with Advisory Committee on Immunization Practices, CDC and WHO guidelines in view of above mentioned statements contrary to the perception of reviewer. 1. Sarah Schillie, MD; Claudia Vellozzi, MD; Arthur Reingold, MD; Aaron Harris, MD; Penina Haber, MPH; John W. Ward, MD; Noele P. Nelson, MD, Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and Reports / January 12, 2018 / 67(1);1–31. 2. World Health Organization. (Hepatitis B vaccines: WHO position paper, July 2017 – Recommendations [published online July 22, 2017]. Vaccine. doi: 10.1016/j.vaccine.2017.07. 2. The author focused on hemodialysis patients. Although eGFR < 60 was defined as CKD, I wondered if patients with eGFR ranging from 15-60 need hemodialysis. The illustration of CKD as a cutoff value of 60 is meaningless. Response : Reviewer either did not read the methodology section in detail or he was unable to comprehend the need of this definition. We want to explain this; usually there are two types of patient on hemodialysis. 1. Patients of CKD 2. Patients with AKI, as our study was limited to CKD patients there was need to define CKD. We included the internationally accepted definition of CKD with reference, we also requested the reviewer in our previous response to provide any alternate definition of CKD with reference, if this definition is not appropriate for this article. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 10 Jun 2021 Muhammad Nadeem , Department of Medicine, Poonch Medical College, Rawalakot, Pakistan 10 Jun 2021 Author Response 1. The authors claimed that all CKD patients should be vaccinated for HBV by guidelines. However, the authors should be more cautious about the claims, all the guidelines did not ... Continue reading 1. The authors claimed that all CKD patients should be vaccinated for HBV by guidelines. However, the authors should be more cautious about the claims, all the guidelines did not recommend vaccination for all CKD patients for HBV. eg. the MMWR report (cited by the author in the revision) clearly indicated that "Vaccination of individuals who possess antibodies against HBV from a previous infection is not necessary" and "Pre-vaccination serologic screening for susceptibility". Furthermore, the CDC guideline did not mention universal HBV vaccination. Response : Reviewer pointed out that "Vaccination of individuals who possess antibodies against HBV from a previous infection is not necessary” and rejected the article on the basis of this statement. No doubt that these individuals do not need the vaccination but routine pre vaccine serology to rule out immune individual in not recommended in any guideline. MMWR report which summarizes recommendations from the Advisory Committee on Immunization Practices (ACIP) and CDC clearly mentions “ACIP recommends vaccination of adults at risk for HBV infection, including universal vaccination of adults in settings in which a high proportion have risk factors for HBV infection” 1 supporting our claims of vaccination of all individuals on hemodialysis. ACIP also mentions “Serologic testing should not be a barrier to vaccination of susceptible persons 1 ” and “Vaccination of persons immune to HBV because of current or previous infection or HepB vaccination does not increase the risk for adverse events” 1 . It clearly indicates that pre vaccination serology is not necessary. CDC also adopted these guidelines. ( https://www.cdc.gov/hepatitis/hbv/vaccadults.htm ) Further reviewer stated "Pre-vaccination serologic screening for susceptibility" but the Advisory Committee on Immunization Practices states “Testing is not a requirement for vaccination, and in settings where testing is not feasible, vaccination of recommended persons should continue 1 ”. Routine pre vaccination serology is also not recommended by WHO especially when it is not cost effective 2 . As routine pre vaccination serology except HBsAg is not done in our setup, so we included all patients except HBsAg positive patient. This is in accordance with Advisory Committee on Immunization Practices, CDC and WHO guidelines in view of above mentioned statements contrary to the perception of reviewer. 1. Sarah Schillie, MD; Claudia Vellozzi, MD; Arthur Reingold, MD; Aaron Harris, MD; Penina Haber, MPH; John W. Ward, MD; Noele P. Nelson, MD, Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and Reports / January 12, 2018 / 67(1);1–31. 2. World Health Organization. (Hepatitis B vaccines: WHO position paper, July 2017 – Recommendations [published online July 22, 2017]. Vaccine. doi: 10.1016/j.vaccine.2017.07. 2. The author focused on hemodialysis patients. Although eGFR < 60 was defined as CKD, I wondered if patients with eGFR ranging from 15-60 need hemodialysis. The illustration of CKD as a cutoff value of 60 is meaningless. Response : Reviewer either did not read the methodology section in detail or he was unable to comprehend the need of this definition. We want to explain this; usually there are two types of patient on hemodialysis. 1. Patients of CKD 2. Patients with AKI, as our study was limited to CKD patients there was need to define CKD. We included the internationally accepted definition of CKD with reference, we also requested the reviewer in our previous response to provide any alternate definition of CKD with reference, if this definition is not appropriate for this article. 1. The authors claimed that all CKD patients should be vaccinated for HBV by guidelines. However, the authors should be more cautious about the claims, all the guidelines did not recommend vaccination for all CKD patients for HBV. eg. the MMWR report (cited by the author in the revision) clearly indicated that "Vaccination of individuals who possess antibodies against HBV from a previous infection is not necessary" and "Pre-vaccination serologic screening for susceptibility". Furthermore, the CDC guideline did not mention universal HBV vaccination. Response : Reviewer pointed out that "Vaccination of individuals who possess antibodies against HBV from a previous infection is not necessary” and rejected the article on the basis of this statement. No doubt that these individuals do not need the vaccination but routine pre vaccine serology to rule out immune individual in not recommended in any guideline. MMWR report which summarizes recommendations from the Advisory Committee on Immunization Practices (ACIP) and CDC clearly mentions “ACIP recommends vaccination of adults at risk for HBV infection, including universal vaccination of adults in settings in which a high proportion have risk factors for HBV infection” 1 supporting our claims of vaccination of all individuals on hemodialysis. ACIP also mentions “Serologic testing should not be a barrier to vaccination of susceptible persons 1 ” and “Vaccination of persons immune to HBV because of current or previous infection or HepB vaccination does not increase the risk for adverse events” 1 . It clearly indicates that pre vaccination serology is not necessary. CDC also adopted these guidelines. ( https://www.cdc.gov/hepatitis/hbv/vaccadults.htm ) Further reviewer stated "Pre-vaccination serologic screening for susceptibility" but the Advisory Committee on Immunization Practices states “Testing is not a requirement for vaccination, and in settings where testing is not feasible, vaccination of recommended persons should continue 1 ”. Routine pre vaccination serology is also not recommended by WHO especially when it is not cost effective 2 . As routine pre vaccination serology except HBsAg is not done in our setup, so we included all patients except HBsAg positive patient. This is in accordance with Advisory Committee on Immunization Practices, CDC and WHO guidelines in view of above mentioned statements contrary to the perception of reviewer. 1. Sarah Schillie, MD; Claudia Vellozzi, MD; Arthur Reingold, MD; Aaron Harris, MD; Penina Haber, MPH; John W. Ward, MD; Noele P. Nelson, MD, Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and Reports / January 12, 2018 / 67(1);1–31. 2. World Health Organization. (Hepatitis B vaccines: WHO position paper, July 2017 – Recommendations [published online July 22, 2017]. Vaccine. doi: 10.1016/j.vaccine.2017.07. 2. The author focused on hemodialysis patients. Although eGFR < 60 was defined as CKD, I wondered if patients with eGFR ranging from 15-60 need hemodialysis. The illustration of CKD as a cutoff value of 60 is meaningless. Response : Reviewer either did not read the methodology section in detail or he was unable to comprehend the need of this definition. We want to explain this; usually there are two types of patient on hemodialysis. 1. Patients of CKD 2. Patients with AKI, as our study was limited to CKD patients there was need to define CKD. We included the internationally accepted definition of CKD with reference, we also requested the reviewer in our previous response to provide any alternate definition of CKD with reference, if this definition is not appropriate for this article. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Version 1 VERSION 1 PUBLISHED 29 Jan 2021 Views 0 Cite How to cite this report: Liu C. Reviewer Report For: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.5256/f1000research.31018.r82554 ) The direct URL for this report is: https://f1000research.com/articles/10-55/v1#referee-response-82554 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 15 Apr 2021 Chenhua Liu , Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan Not Approved VIEWS 0 https://doi.org/10.5256/f1000research.31018.r82554 Nadeem et al. conducted an observational study about the vaccination status in Pakistan and to correlated the socioeconomic status with HBV vaccination. Major concerns: The authors interviewed the vaccination status in all patients. ... Continue reading READ ALL Nadeem et al. conducted an observational study about the vaccination status in Pakistan and to correlated the socioeconomic status with HBV vaccination. Major concerns: The authors interviewed the vaccination status in all patients. However, the patients had prone to have a high probability of recall bias, making sampling interviewing not reliable. Furthermore, patients who had HBsAg (-)/anti-HBs (+)/anti-HBc (-) or HBsAg (-)/anti-HBs (+)/anti-HBC (+) did not need vaccination. Furthermore, patients with isolated anti-HBc (+) may not need vaccination. The lack of HBV status in all patients is not scientific and should be comprehensively assessed. Why did the author define CKD as eGFR 30 need not receive hemodialysis. The authors poorly defined the patient in this study. Since this was an observational study without any pre-specified hypothesis, a sample size calculation was not needed. The author erroneously cited and used the sample size calculation in the study. Is the work clearly and accurately presented and does it cite the current literature? No Is the study design appropriate and is the work technically sound? No Are sufficient details of methods and analysis provided to allow replication by others? No If applicable, is the statistical analysis and its interpretation appropriate? No Are all the source data underlying the results available to ensure full reproducibility? No source data required Are the conclusions drawn adequately supported by the results? No Competing Interests: No competing interests were disclosed. Reviewer Expertise: Hepatitis B, hepatitis C, chronic kidney disease I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Liu C. Reviewer Report For: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.5256/f1000research.31018.r82554 ) The direct URL for this report is: https://f1000research.com/articles/10-55/v1#referee-response-82554 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 29 Apr 2021 Muhammad Nadeem , Department of Medicine, Poonch Medical College, Rawalakot, Pakistan 29 Apr 2021 Author Response I would like to thank the reviewer for reviewing the article and giving his precious time and valuable comments. Reviewer had few concerns regarding the study, as a corresponding author I ... Continue reading I would like to thank the reviewer for reviewing the article and giving his precious time and valuable comments. Reviewer had few concerns regarding the study, as a corresponding author I want to respond on this report. 1. Main concern of the reviewer was about data collection. According to reviewer interviewing the patient regarding vaccination is not a reliable method, it is a genuine concern but due to unavailability of formal certification of hepatitis B vaccination in our setup we were left only with this method. Although we counter checked the information provided by the patient from record of dialysis centers which we did not mention in methodology. I would like to add this in data collection procedure. 2. According to reviewer “patients who had HBsAg (-)/anti-HBs (+)/anti-HBc (-) or HBsAg (-)/anti-HBs (+)/anti-HBC (+) did not need vaccination. Furthermore, patients with isolated anti-HBc (+) may not need vaccination.” This statement does not match the recommendations of CDC, WHO and Nephrology societies, as they recommend the vaccination of all CKD patients [1,2,3,4]. Routine pre vaccination serology is also not recommended by WHO especially when it is not cost effective [5]. The only logical cost effective serological test is HBsAg as there is no benefit of vaccination in HBsAg positive patients not the HBsAg negative as mentioned by reviewer, we did this and excluded the HBsAg positive patients mentioned in data collection procedure. If reviewer can provide the reference regarding the recommendation of all these serological tests before vaccination in CKD and exclusion of patients with serological results mentioned in his statement it will help us and other researchers in future. 3. Another observation was regarding definition of CKD. Definition provided is internationally accepted definition established by The Kidney Disease Outcomes Quality Initiative (KDOQI) of the National Kidney Foundation (NKF) and Kidney Disease Improving Global Outcomes (KDIGO) [4]. This definition cannot be changed; if reviewer can provide some other definition with reference we can include that definition. As for as selection of patients for this study is concerned it is clearly mentioned that only those patients of CKD were included who were on regular hemodialysis, so the observation of reviewer “Lots of patients with eGFR > 30 need not receive hemodialysis. The authors poorly defined the patient in this study” is not justified. 4. As for as details of sample size calculation are concerned, these were not included in initial manuscript. These details were provided on the demand of journal. References: 1. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep. 1982;31(24):317–22. , 27-8. 2. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep. 1993;42:1–18. 3. Guidelines for vaccination in patients with chronic kidney disease. Indian J Nephrol. 2016; 26(Suppl 1): S15–S18. 4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1-150; http://dx.doi.org/10.1038/kisup.2012.73 5. World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 – Recommendations [published online July 22, 2017]. Vaccine. doi: 10.1016/j.vaccine.2017.07.046) I would like to thank the reviewer for reviewing the article and giving his precious time and valuable comments. Reviewer had few concerns regarding the study, as a corresponding author I want to respond on this report. 1. Main concern of the reviewer was about data collection. According to reviewer interviewing the patient regarding vaccination is not a reliable method, it is a genuine concern but due to unavailability of formal certification of hepatitis B vaccination in our setup we were left only with this method. Although we counter checked the information provided by the patient from record of dialysis centers which we did not mention in methodology. I would like to add this in data collection procedure. 2. According to reviewer “patients who had HBsAg (-)/anti-HBs (+)/anti-HBc (-) or HBsAg (-)/anti-HBs (+)/anti-HBC (+) did not need vaccination. Furthermore, patients with isolated anti-HBc (+) may not need vaccination.” This statement does not match the recommendations of CDC, WHO and Nephrology societies, as they recommend the vaccination of all CKD patients [1,2,3,4]. Routine pre vaccination serology is also not recommended by WHO especially when it is not cost effective [5]. The only logical cost effective serological test is HBsAg as there is no benefit of vaccination in HBsAg positive patients not the HBsAg negative as mentioned by reviewer, we did this and excluded the HBsAg positive patients mentioned in data collection procedure. If reviewer can provide the reference regarding the recommendation of all these serological tests before vaccination in CKD and exclusion of patients with serological results mentioned in his statement it will help us and other researchers in future. 3. Another observation was regarding definition of CKD. Definition provided is internationally accepted definition established by The Kidney Disease Outcomes Quality Initiative (KDOQI) of the National Kidney Foundation (NKF) and Kidney Disease Improving Global Outcomes (KDIGO) [4]. This definition cannot be changed; if reviewer can provide some other definition with reference we can include that definition. As for as selection of patients for this study is concerned it is clearly mentioned that only those patients of CKD were included who were on regular hemodialysis, so the observation of reviewer “Lots of patients with eGFR > 30 need not receive hemodialysis. The authors poorly defined the patient in this study” is not justified. 4. As for as details of sample size calculation are concerned, these were not included in initial manuscript. These details were provided on the demand of journal. References: 1. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep. 1982;31(24):317–22. , 27-8. 2. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep. 1993;42:1–18. 3. Guidelines for vaccination in patients with chronic kidney disease. Indian J Nephrol. 2016; 26(Suppl 1): S15–S18. 4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1-150; http://dx.doi.org/10.1038/kisup.2012.73 5. World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 – Recommendations [published online July 22, 2017]. Vaccine. doi: 10.1016/j.vaccine.2017.07.046) Competing Interests: I am corresponding author for this article Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 29 Apr 2021 Muhammad Nadeem , Department of Medicine, Poonch Medical College, Rawalakot, Pakistan 29 Apr 2021 Author Response I would like to thank the reviewer for reviewing the article and giving his precious time and valuable comments. Reviewer had few concerns regarding the study, as a corresponding author I ... Continue reading I would like to thank the reviewer for reviewing the article and giving his precious time and valuable comments. Reviewer had few concerns regarding the study, as a corresponding author I want to respond on this report. 1. Main concern of the reviewer was about data collection. According to reviewer interviewing the patient regarding vaccination is not a reliable method, it is a genuine concern but due to unavailability of formal certification of hepatitis B vaccination in our setup we were left only with this method. Although we counter checked the information provided by the patient from record of dialysis centers which we did not mention in methodology. I would like to add this in data collection procedure. 2. According to reviewer “patients who had HBsAg (-)/anti-HBs (+)/anti-HBc (-) or HBsAg (-)/anti-HBs (+)/anti-HBC (+) did not need vaccination. Furthermore, patients with isolated anti-HBc (+) may not need vaccination.” This statement does not match the recommendations of CDC, WHO and Nephrology societies, as they recommend the vaccination of all CKD patients [1,2,3,4]. Routine pre vaccination serology is also not recommended by WHO especially when it is not cost effective [5]. The only logical cost effective serological test is HBsAg as there is no benefit of vaccination in HBsAg positive patients not the HBsAg negative as mentioned by reviewer, we did this and excluded the HBsAg positive patients mentioned in data collection procedure. If reviewer can provide the reference regarding the recommendation of all these serological tests before vaccination in CKD and exclusion of patients with serological results mentioned in his statement it will help us and other researchers in future. 3. Another observation was regarding definition of CKD. Definition provided is internationally accepted definition established by The Kidney Disease Outcomes Quality Initiative (KDOQI) of the National Kidney Foundation (NKF) and Kidney Disease Improving Global Outcomes (KDIGO) [4]. This definition cannot be changed; if reviewer can provide some other definition with reference we can include that definition. As for as selection of patients for this study is concerned it is clearly mentioned that only those patients of CKD were included who were on regular hemodialysis, so the observation of reviewer “Lots of patients with eGFR > 30 need not receive hemodialysis. The authors poorly defined the patient in this study” is not justified. 4. As for as details of sample size calculation are concerned, these were not included in initial manuscript. These details were provided on the demand of journal. References: 1. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep. 1982;31(24):317–22. , 27-8. 2. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep. 1993;42:1–18. 3. Guidelines for vaccination in patients with chronic kidney disease. Indian J Nephrol. 2016; 26(Suppl 1): S15–S18. 4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1-150; http://dx.doi.org/10.1038/kisup.2012.73 5. World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 – Recommendations [published online July 22, 2017]. Vaccine. doi: 10.1016/j.vaccine.2017.07.046) I would like to thank the reviewer for reviewing the article and giving his precious time and valuable comments. Reviewer had few concerns regarding the study, as a corresponding author I want to respond on this report. 1. Main concern of the reviewer was about data collection. According to reviewer interviewing the patient regarding vaccination is not a reliable method, it is a genuine concern but due to unavailability of formal certification of hepatitis B vaccination in our setup we were left only with this method. Although we counter checked the information provided by the patient from record of dialysis centers which we did not mention in methodology. I would like to add this in data collection procedure. 2. According to reviewer “patients who had HBsAg (-)/anti-HBs (+)/anti-HBc (-) or HBsAg (-)/anti-HBs (+)/anti-HBC (+) did not need vaccination. Furthermore, patients with isolated anti-HBc (+) may not need vaccination.” This statement does not match the recommendations of CDC, WHO and Nephrology societies, as they recommend the vaccination of all CKD patients [1,2,3,4]. Routine pre vaccination serology is also not recommended by WHO especially when it is not cost effective [5]. The only logical cost effective serological test is HBsAg as there is no benefit of vaccination in HBsAg positive patients not the HBsAg negative as mentioned by reviewer, we did this and excluded the HBsAg positive patients mentioned in data collection procedure. If reviewer can provide the reference regarding the recommendation of all these serological tests before vaccination in CKD and exclusion of patients with serological results mentioned in his statement it will help us and other researchers in future. 3. Another observation was regarding definition of CKD. Definition provided is internationally accepted definition established by The Kidney Disease Outcomes Quality Initiative (KDOQI) of the National Kidney Foundation (NKF) and Kidney Disease Improving Global Outcomes (KDIGO) [4]. This definition cannot be changed; if reviewer can provide some other definition with reference we can include that definition. As for as selection of patients for this study is concerned it is clearly mentioned that only those patients of CKD were included who were on regular hemodialysis, so the observation of reviewer “Lots of patients with eGFR > 30 need not receive hemodialysis. The authors poorly defined the patient in this study” is not justified. 4. As for as details of sample size calculation are concerned, these were not included in initial manuscript. These details were provided on the demand of journal. References: 1. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep. 1982;31(24):317–22. , 27-8. 2. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep. 1993;42:1–18. 3. Guidelines for vaccination in patients with chronic kidney disease. Indian J Nephrol. 2016; 26(Suppl 1): S15–S18. 4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1-150; http://dx.doi.org/10.1038/kisup.2012.73 5. World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 – Recommendations [published online July 22, 2017]. Vaccine. doi: 10.1016/j.vaccine.2017.07.046) Competing Interests: I am corresponding author for this article Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 3 VERSION 3 PUBLISHED 29 Jan 2021 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 3 Version 3 (revision) 11 Jun 24 read Version 2 (revision) 29 Apr 21 read read Version 1 29 Jan 21 read Chenhua Liu , National Taiwan University Hospital, Taipei, Taiwan Lionel Rostaing , Université Grenoble Alpes, Grenoble, France Antonio Bertoletti , Duke-NUS Medical School, Singapore, Singapore Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Bertoletti A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 31 Dec 2024 | for Version 3 Antonio Bertoletti , Duke-NUS Medical School, Singapore, Singapore 0 Views copyright © 2025 Bertoletti A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions This is an observational study based on a questionnaire. The authors derived from this questionnaire that about half of the patients on regular hemodialysis were vaccinated against HBV and that the vaccination status was linked with socioeconomic status. There is nothing more. No analysis of HBV prevalence..no test whether the vaccinated here reallly Ab-HBs positive. I don't have any comment except to say that the results are not exactly of high interest. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise HBv pathogenesis. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 30 Jan 2025 Muhammad Nadeem, Department of Medicine, Poonch Medical College, Rawalakot, Pakistan I would like to thank you for your precocious time and valuable comments about our article; this will guide us in future as well. You rightly pointed out that we did not mention about the prevalence of Hep B. We did the Hep B surface antigen but all those patients who were Hep B surface antigen positive were excluded from the study as mentioned in Study design and sampling " Hepatitis B surface antigen positive, newly diagnosed CKD patients not on dialysis and patients not sure about their vaccination status were excluded from the study" that's why it was not mentioned. You also rightly mentioned that results are not interesting but in our circumstances where dialysis centers and nephrologist are not following the guidelines of vaccinating every CKD patients these results can be used to sensitize them to improve the vaccination rates. I hope you will again review the article considering our limitations and local circumstances as for as the results are concerned and approve our article without reservations. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Bertoletti A. Peer Review Report For: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.5256/f1000research.167732.r351017) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/10-55/v3#referee-response-351017 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2022 Rostaing L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 08 Nov 2022 | for Version 2 Lionel Rostaing , Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, Centre Hospitalier Universitaire Grenoble Alpes (CHU), Université Grenoble Alpes, Grenoble, France 0 Views copyright © 2022 Rostaing L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions This is an observational descriptive study that was conducted in 2 departments of hemodialysis in Azad-Kashmir (Pakistan). The study took place between March and July 2019. HBV infection still remains a public health problem in many Asian countries. In addition, its prevalence amongst hemodialysis patients is increased (i.e., because of nosocomial transmission). It is therefore of utmost importance to limit the spread of HVB infection in hemodialysis patients: this can only be achieved with universal HBV vaccination. However, many people are reluctant to HBV vaccination. In this original work, Nadeem M. et al . looked at the factors associated with HBV vaccination in a cohort of 149 hemodialysis patients; of these 63.1% were male. Overall, 24.2% were uneducated, 33.6% had 1-10 years school education, 38.2% had 10-14 years education, and 4% had more than 14 years education. In addition, about 35% patients were from low socioeconomic class, 54% from middle and 11% from higher class. At the end the of the day, only 45.6% (n=68) of patients were vaccinated. In addition, vaccination status was significantly associated with education (p=0.004) and socioeconomic status (p=0.008). In the discussion’s section the authors should emphasize the fact that educational programs should be implemented in chronic kidney disease patients as well as in hemodialysis ones in order that they are aware of the importance of « fighting » HBV infection. Indeed, HBV vaccination should be done for free as well as the boosters (is it the case in Pakistan?). Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Nephrology, Dialysis, Kidney transplantation, Transplant Immunology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 16 Nov 2022 Muhammad Nadeem, Department of Medicine, Poonch Medical College, Rawalakot, Pakistan We would like to thank the reviewer for his valuable time and comments on our article; this will be very helpful for us in future research as well. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Rostaing L. Peer Review Report For: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.5256/f1000research.56293.r153704) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/10-55/v2#referee-response-153704 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2021 Liu C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 29 Apr 2021 | for Version 2 Chenhua Liu , Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan 0 Views copyright © 2021 Liu C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Not Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The authors claimed that all CKD patients should be vaccinated for HBV by guidelines. However, the authors should be more cautious about the claims, all the guidelines did not recommend vaccination for all CKD patients for HBV. eg. the MMWR report (cited by the author in the revision) clearly indicated that "Vaccination of individuals who possess antibodies against HBV from a previous infection is not necessary" and "Pre-vaccination serologic screening for susceptibility". Furthermore, the CDC guideline did not mention universal HBV vaccination. The author focused on hemodialysis patients. Although eGFR < 60 was defined as CKD, I wondered if patients with eGFR ranging from 15-60 need hemodialysis. The illustration of CKD as a cutoff value of 60 is meaningless. Competing Interests No competing interests were disclosed. Reviewer Expertise Hepatitis B, hepatitis C, chronic kidney disease I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. reply Respond to this report Responses (1) Author Response 10 Jun 2021 Muhammad Nadeem, Department of Medicine, Poonch Medical College, Rawalakot, Pakistan 1. The authors claimed that all CKD patients should be vaccinated for HBV by guidelines. However, the authors should be more cautious about the claims, all the guidelines did not recommend vaccination for all CKD patients for HBV. eg. the MMWR report (cited by the author in the revision) clearly indicated that "Vaccination of individuals who possess antibodies against HBV from a previous infection is not necessary" and "Pre-vaccination serologic screening for susceptibility". Furthermore, the CDC guideline did not mention universal HBV vaccination. Response : Reviewer pointed out that "Vaccination of individuals who possess antibodies against HBV from a previous infection is not necessary” and rejected the article on the basis of this statement. No doubt that these individuals do not need the vaccination but routine pre vaccine serology to rule out immune individual in not recommended in any guideline. MMWR report which summarizes recommendations from the Advisory Committee on Immunization Practices (ACIP) and CDC clearly mentions “ACIP recommends vaccination of adults at risk for HBV infection, including universal vaccination of adults in settings in which a high proportion have risk factors for HBV infection” 1 supporting our claims of vaccination of all individuals on hemodialysis. ACIP also mentions “Serologic testing should not be a barrier to vaccination of susceptible persons 1 ” and “Vaccination of persons immune to HBV because of current or previous infection or HepB vaccination does not increase the risk for adverse events” 1 . It clearly indicates that pre vaccination serology is not necessary. CDC also adopted these guidelines. ( https://www.cdc.gov/hepatitis/hbv/vaccadults.htm ) Further reviewer stated "Pre-vaccination serologic screening for susceptibility" but the Advisory Committee on Immunization Practices states “Testing is not a requirement for vaccination, and in settings where testing is not feasible, vaccination of recommended persons should continue 1 ”. Routine pre vaccination serology is also not recommended by WHO especially when it is not cost effective 2 . As routine pre vaccination serology except HBsAg is not done in our setup, so we included all patients except HBsAg positive patient. This is in accordance with Advisory Committee on Immunization Practices, CDC and WHO guidelines in view of above mentioned statements contrary to the perception of reviewer. 1. Sarah Schillie, MD; Claudia Vellozzi, MD; Arthur Reingold, MD; Aaron Harris, MD; Penina Haber, MPH; John W. Ward, MD; Noele P. Nelson, MD, Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and Reports / January 12, 2018 / 67(1);1–31. 2. World Health Organization. (Hepatitis B vaccines: WHO position paper, July 2017 – Recommendations [published online July 22, 2017]. Vaccine. doi: 10.1016/j.vaccine.2017.07. 2. The author focused on hemodialysis patients. Although eGFR < 60 was defined as CKD, I wondered if patients with eGFR ranging from 15-60 need hemodialysis. The illustration of CKD as a cutoff value of 60 is meaningless. Response : Reviewer either did not read the methodology section in detail or he was unable to comprehend the need of this definition. We want to explain this; usually there are two types of patient on hemodialysis. 1. Patients of CKD 2. Patients with AKI, as our study was limited to CKD patients there was need to define CKD. We included the internationally accepted definition of CKD with reference, we also requested the reviewer in our previous response to provide any alternate definition of CKD with reference, if this definition is not appropriate for this article. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Liu C. Peer Review Report For: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.5256/f1000research.56293.r84207) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/10-55/v2#referee-response-84207 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2021 Liu C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 15 Apr 2021 | for Version 1 Chenhua Liu , Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan 0 Views copyright © 2021 Liu C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Not Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Nadeem et al. conducted an observational study about the vaccination status in Pakistan and to correlated the socioeconomic status with HBV vaccination. Major concerns: The authors interviewed the vaccination status in all patients. However, the patients had prone to have a high probability of recall bias, making sampling interviewing not reliable. Furthermore, patients who had HBsAg (-)/anti-HBs (+)/anti-HBc (-) or HBsAg (-)/anti-HBs (+)/anti-HBC (+) did not need vaccination. Furthermore, patients with isolated anti-HBc (+) may not need vaccination. The lack of HBV status in all patients is not scientific and should be comprehensively assessed. Why did the author define CKD as eGFR 30 need not receive hemodialysis. The authors poorly defined the patient in this study. Since this was an observational study without any pre-specified hypothesis, a sample size calculation was not needed. The author erroneously cited and used the sample size calculation in the study. Is the work clearly and accurately presented and does it cite the current literature? No Is the study design appropriate and is the work technically sound? No Are sufficient details of methods and analysis provided to allow replication by others? No If applicable, is the statistical analysis and its interpretation appropriate? No Are all the source data underlying the results available to ensure full reproducibility? No source data required Are the conclusions drawn adequately supported by the results? No Competing Interests No competing interests were disclosed. Reviewer Expertise Hepatitis B, hepatitis C, chronic kidney disease I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above. reply Respond to this report Responses (1) Author Response 29 Apr 2021 Muhammad Nadeem, Department of Medicine, Poonch Medical College, Rawalakot, Pakistan I would like to thank the reviewer for reviewing the article and giving his precious time and valuable comments. Reviewer had few concerns regarding the study, as a corresponding author I want to respond on this report. 1. Main concern of the reviewer was about data collection. According to reviewer interviewing the patient regarding vaccination is not a reliable method, it is a genuine concern but due to unavailability of formal certification of hepatitis B vaccination in our setup we were left only with this method. Although we counter checked the information provided by the patient from record of dialysis centers which we did not mention in methodology. I would like to add this in data collection procedure. 2. According to reviewer “patients who had HBsAg (-)/anti-HBs (+)/anti-HBc (-) or HBsAg (-)/anti-HBs (+)/anti-HBC (+) did not need vaccination. Furthermore, patients with isolated anti-HBc (+) may not need vaccination.” This statement does not match the recommendations of CDC, WHO and Nephrology societies, as they recommend the vaccination of all CKD patients [1,2,3,4]. Routine pre vaccination serology is also not recommended by WHO especially when it is not cost effective [5]. The only logical cost effective serological test is HBsAg as there is no benefit of vaccination in HBsAg positive patients not the HBsAg negative as mentioned by reviewer, we did this and excluded the HBsAg positive patients mentioned in data collection procedure. If reviewer can provide the reference regarding the recommendation of all these serological tests before vaccination in CKD and exclusion of patients with serological results mentioned in his statement it will help us and other researchers in future. 3. Another observation was regarding definition of CKD. Definition provided is internationally accepted definition established by The Kidney Disease Outcomes Quality Initiative (KDOQI) of the National Kidney Foundation (NKF) and Kidney Disease Improving Global Outcomes (KDIGO) [4]. This definition cannot be changed; if reviewer can provide some other definition with reference we can include that definition. As for as selection of patients for this study is concerned it is clearly mentioned that only those patients of CKD were included who were on regular hemodialysis, so the observation of reviewer “Lots of patients with eGFR > 30 need not receive hemodialysis. The authors poorly defined the patient in this study” is not justified. 4. As for as details of sample size calculation are concerned, these were not included in initial manuscript. These details were provided on the demand of journal. References: 1. Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep. 1982;31(24):317–22. , 27-8. 2. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep. 1993;42:1–18. 3. Guidelines for vaccination in patients with chronic kidney disease. Indian J Nephrol. 2016; 26(Suppl 1): S15–S18. 4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1-150; http://dx.doi.org/10.1038/kisup.2012.73 5. World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 – Recommendations [published online July 22, 2017]. Vaccine. doi: 10.1016/j.vaccine.2017.07.046) View more View less Competing Interests I am corresponding author for this article reply Respond Report a concern Liu C. Peer Review Report For: Vaccination against hepatitis B virus in hemodialysis patients: trends in dialysis centers of Northern Pakistan [version 3; peer review: 1 approved, 1 approved with reservations, 1 not approved] . F1000Research 2024, 10 :55 ( https://doi.org/10.5256/f1000research.31018.r82554) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/10-55/v1#referee-response-82554 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Vaccination against hepatitis B virus in...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/10-55/v3" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/10-55/v3&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/10-55/v3" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Nadeem M et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/10-55/v3/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/10-55", templates : { twitter : "Vaccination against hepatitis B virus in hemodialysis patients:.... Nadeem M et al., published by " + "@F1000Research" + ", https://f1000research.com/articles/10-55/v3" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/28045/167732") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "167732"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "323340": 0, "323337": 0, "323338": 0, "323339": 0, "153617": 0, "323344": 0, "323345": 0, "298524": 0, "298525": 0, "298526": 0, "298527": 0, "298520": 0, "298521": 0, "94751": 0, "298522": 0, "94750": 0, "298523": 0, "94753": 0, "94752": 0, "94755": 0, "94754": 0, "94757": 0, "298528": 0, "298529": 0, "351021": 0, "351020": 0, "351023": 0, "351022": 0, "351017": 7, "351016": 0, "351019": 0, "351018": 0, "351025": 0, "80181": 0, "80180": 0, "351027": 0, "359999": 0, "359998": 0, "87613": 0, "147006": 0, "87612": 0, "147007": 0, "87614": 0, "147005": 0, "147008": 0, "360001": 0, "360000": 0, "315724": 0, "315725": 0, "315726": 0, "315727": 0, "315721": 0, "315722": 0, "315723": 0, "315728": 0, "315729": 0, "315730": 0, "289887": 0, "84067": 0, "146790": 0, "289888": 0, "84069": 0, "146791": 0, "84068": 0, "153704": 12, "90735": 0, "90734": 0, "90740": 0, "82551": 0, "303996": 0, "82553": 0, "303997": 0, "82552": 0, "303998": 0, "82555": 0, "303999": 0, "82554": 27, "304004": 0, "304005": 0, "304000": 0, "304001": 0, "304002": 0, "304003": 0, "371607": 0, "371613": 0, "371612": 0, "371614": 0, "155038": 0, "371609": 0, "155039": 0, "371608": 0, "297370": 0, "371611": 0, "297371": 0, "371610": 0, "79269": 0, "79270": 0, "136116": 0, "308173": 0, "308174": 0, "308175": 0, "308180": 0, "145875": 0, "308181": 0, "312790": 0, "308182": 0, "312791": 0, "308176": 0, "308177": 0, "308178": 0, "145877": 0, "308179": 0, "312796": 0, "145883": 0, "312797": 0, "84443": 0, "312798": 0, "312799": 0, "312792": 0, "84444": 0, "312793": 0, "312794": 0, "312795": 0, "355813": 0, "355812": 0, "355815": 0, "355814": 0, "355809": 0, "355808": 0, "355811": 0, "355810": 0, "355817": 0, "355816": 0, "84207": 26, "78575": 0, "78574": 0, "78577": 0, "78576": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "2f0e81a2-4df0-4cb8-9265-58fe0e291b75"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });